Wt1 Antibody

What is the WT1 protein and why is it significant as a target for antibody-based applications?

WT1 (Wilms' Tumor 1) is a zinc finger transcription factor initially identified as a tumor suppressor gene involved in Wilms' tumor, a pediatric kidney cancer. The protein has a molecular weight of approximately 49.2 kDa and plays crucial roles in cellular proliferation, differentiation, apoptosis, and organogenesis .

WT1 is significant in research for several reasons:

• It functions as both a transcriptional activator and repressor depending on cellular context

• It is overexpressed in multiple malignancies including leukemias, glioblastoma, and various solid tumors

• It serves as a marker for identifying specific cell types, particularly mesothelial cells

• It has emerged as a promising immunotherapeutic target due to its tumor-specific overexpression pattern

In normal tissues, WT1 expression is limited to kidney, spleen, gonadal ridge mesoderm, Sertoli cells of testes, and granulosa cells of the ovary . This restricted normal tissue expression combined with overexpression in malignancies makes it an excellent target for cancer diagnostics and potential therapies.

What epitope regions of WT1 are commonly targeted by research antibodies and why does this matter?

Different WT1 antibodies target various epitope regions, each with specific research implications:

Epitope selection matters because:

• Some WT1 antibodies recognize all isoforms while others are isoform-specific

• Truncated forms of WT1 (lacking zinc finger domains) may have distinct immunogenicity

• Different epitopes may be accessible depending on protein conformation or interactions

• For immunotherapy monitoring, epitope-specific antibodies allow tracking of immune responses to specific vaccine peptides

How do you validate the specificity of a WT1 antibody for research applications?

Proper validation of WT1 antibodies requires multiple approaches:

• Positive and negative control samples:

  • Positive controls: K-562 cells, A431 cells, MCF-7 cells, MOLT-4 cells, kidney tissue

  • Negative controls: Cell lines known not to express WT1 or with WT1 knockout

• Multiple detection methods:

  • Western blot: Confirm single band at expected molecular weight (49-55 kDa)

  • Immunoprecipitation followed by mass spectrometry

  • Immunofluorescence: Verify expected subcellular localization (nuclear, paranuclear)

• Knockdown/knockout validation:

  • siRNA or CRISPR-based WT1 knockdown/knockout cells

  • Verify signal reduction/elimination in Western blot, IF, and other applications

• Cross-reactivity assessment:

  • For antibodies claimed to work across species, confirm specificity in each species

  • Test on recombinant WT1 protein variants to confirm isoform specificity

• Application-specific validation:

  • For ChIP applications: Include control regions not bound by WT1

  • For IHC/IF: Include absorption controls with immunizing peptide

Validation data should be documented with appropriate positive and negative controls for each application intended .

How can WT1 antibodies be optimally used to monitor immune responses to WT1 peptide vaccines?

Monitoring immune responses to WT1 peptide vaccines requires sophisticated antibody-based techniques:

Methodology for epitope-specific antibody monitoring:

• ELISA-based detection of patient anti-WT1 antibodies:

  • Coat plates with specific WT1 peptides (e.g., WT1-235, WT1-271, WT1-332)

  • Determine baseline pre-vaccination antibody levels

  • Monitor IgG and IgM responses over time

  • Establish cutoff values: typically mean absorbance + 2 standard deviations from negative controls

• Flow cytometry detection:

  • Incubate T2 or T2-2402 cells with WT1 peptides (e.g., WT1-235, CYTWNQMNL)

  • Add patient sera followed by fluorochrome-conjugated anti-human IgG

  • Analyze peptide-specific antibody binding to cell surface

• Analysis of IgG subclasses:

  • Determine IgG1/IgG2 ratios to assess Th1/Th2 polarization

  • Th1-type IgG antibody (IgG1 and IgG3) predominance indicates favorable response

Clinical correlations with antibody monitoring:

Importantly, monitoring multiple epitope-specific antibodies (not just the vaccine target epitope) provides more comprehensive insight into the breadth of immune response .

What methodological considerations are crucial when using WT1 antibodies to distinguish between WT1 isoforms in cancer research?

Distinguishing between WT1 isoforms requires careful antibody selection and experimental design:

Key WT1 isoform variations:

• Alternative splicing at exon 5 (+/- 17aa)

• Alternative splicing at exon 9 (+/- 3aa KTS)

• Alternative translation start sites

• Truncated forms frequently found in tumors

Methodological approaches:

• Isoform-specific antibody selection:

  • Use antibodies targeting exon junction regions for splice variant detection

  • For truncated variants, use antibodies targeting N-terminal regions that recognize variants lacking zinc finger domains

  • Example: BC.6F-H2 clone recognizes all isoforms including those lacking exon 2-encoded amino acids

• Western blot optimization:

  • Use high-resolution SDS-PAGE (10-12%) for optimal separation of closely-sized isoforms

  • Include positive controls for specific isoforms

  • Consider 2D gel electrophoresis for complex isoform patterns

• RT-PCR complementation:

  • Combine antibody-based detection with isoform-specific RT-PCR

  • Design primers spanning exon junctions (e.g., exon 5 or KTS region)

• Immunoprecipitation with isoform-specific analysis:

  • Immunoprecipitate with broad-specificity WT1 antibody

  • Analyze precipitated proteins with isoform-specific antibodies or mass spectrometry

For research requiring absolute isoform specificity, validation using recombinant WT1 isoforms and WT1-knockout cells with re-expression of specific isoforms is strongly recommended.

What are the optimal conditions for using WT1 antibodies in ChIP experiments to study WT1's transcriptional regulatory functions?

Chromatin immunoprecipitation (ChIP) with WT1 antibodies requires specific considerations:

Antibody selection for ChIP:

• Choose antibodies validated specifically for ChIP applications

• Prefer antibodies targeting regions not involved in DNA binding (N-terminal region) to avoid epitope masking

• Consider using multiple antibodies targeting different epitopes to confirm results

Optimized ChIP protocol for WT1:

• Crosslinking optimization:

  • Standard 1% formaldehyde for 10 minutes at room temperature

  • For challenging targets, consider dual crosslinking with DSG (disuccinimidyl glutarate) followed by formaldehyde

• Sonication parameters:

  • Aim for chromatin fragments of 200-500 bp

  • Verify fragmentation efficiency before proceeding

• Immunoprecipitation conditions:

  • Use 2-5 μg antibody per ChIP reaction

  • Include IgG control and positive control antibody (e.g., RNA Pol II)

  • Extend incubation time to overnight at 4°C with rotation

• Washing stringency:

  • Include high-salt wash steps to reduce background

  • Consider including lithium chloride wash for improved specificity

• Data analysis considerations:

  • Include known WT1 binding sites as positive controls (e.g., EGR1 consensus sequence regions)

  • Analyze enriched regions for WT1 binding motifs

  • Consider ChIP-seq for genome-wide binding profile

Controls and validation:

• Include WT1-knockout or knockdown samples as negative controls

• Validate ChIP-identified targets with reporter assays

• Confirm binding site functionality with site-directed mutagenesis

The truncated WT1 version (Ad-tWT1) lacking zinc finger domains should not be used for studies requiring DNA binding function assessment .

How can WT1 antibodies be effectively used to evaluate WT1-targeted immunotherapies?

WT1 antibodies play crucial roles in developing and evaluating WT1-targeted immunotherapies through multiple methodologies:

Pre-clinical evaluation:

• Target validation in tumor samples:

  • IHC assessment of WT1 expression in tumor biopsies

  • Quantification of expression levels and cellular localization

  • Comparison with normal tissue expression patterns

• Monitoring vaccine construct expression:

  • Verification of truncated WT1 protein expression in dendritic cells

  • Intracellular vs. surface localization assessment

  • Example: Ad-tWT1 vector expression in dendritic cells showed cytoplasmic localization despite encoding a transcription factor

Clinical trial monitoring:

• Epitope-specific antibody responses:

  • Monitor patient-generated antibodies against multiple WT1 epitopes

  • Track IgG and IgM responses to both target and non-target epitopes

  • Assess correlation between antibody production and clinical outcomes

• Comparative analysis of antibody classes:

  Antibody Type	Detection Rate	Significance
  WT1-235 IgM	9.6% pre-vaccination	Limited baseline presence
  WT1-235 IgG	33.3% post-vaccination	Associated with longer survival
  WT1-271 IgM	64.5% pre-vaccination	Marker for pre-existing WT1 immunity
  WT1-332 IgM	12.9% pre-vaccination	Limited baseline presence

• Correlating humoral and cellular responses:

  • Compare antibody production with delayed-type hypersensitivity responses

  • Evaluate relationship between antibody responses and WT1-specific CTL induction

  • Investigate potential suppressive effects of pre-existing antibodies on vaccine efficacy

What protocols maximize sensitivity when using WT1 antibodies to detect minimal residual disease in leukemia?

Detecting minimal residual disease (MRD) in leukemia using WT1 antibodies requires optimized protocols:

Sample preparation optimization:

• Cell enrichment techniques:

  • Perform density gradient centrifugation for peripheral blood/bone marrow

  • Consider CD34+ cell enrichment for improved sensitivity

  • Implement erythrocyte lysis protocols that preserve antigen integrity

• Fixation and permeabilization:

  • Optimize fixation conditions: 10% formalin fixation followed by permeabilization with dedicated solutions

  • Maintain cold chain throughout processing to prevent epitope degradation

  • Standardize timing between collection and processing

Detection methods with enhanced sensitivity:

• Multiparameter flow cytometry:

  • Combine WT1 antibody with leukemia-associated immunophenotype markers

  • Implement sequential gating strategy to identify rare WT1+ cells

  • Collect minimum of 500,000 events for sensitivity below 10^-4

• Immunocytochemistry with signal amplification:

  • Use biotin-streptavidin amplification systems

  • Implement tyramide signal amplification for ultra-sensitive detection

  • Example protocol: Primary anti-WT1 (1:50 dilution) → biotin-conjugated secondary (1:2000) → ABC kit → diaminobenzidine development

• Digital pathology quantification:

  • Utilize automated image analysis for objective quantification

  • Establish standardized intensity thresholds for positivity

  • Compare with WT1 mRNA quantification for validation

Validation and quality control:

• Sensitivity determination:

  • Prepare serial dilutions of WT1+ cells in WT1- cells

  • Establish lower limit of detection (typically 1:10,000 cells)

  • Include spike-in controls with each patient sample

• Standardization recommendations:

  • Use standardized antibody concentrations and incubation conditions

  • Include calibration beads for flow cytometry applications

  • Participate in external quality assessment programs

For maximum sensitivity, consider combining antibody-based detection with molecular methods like RT-PCR for WT1 mRNA quantification as complementary approaches.

What are the most common false positives/negatives when using WT1 antibodies and how can they be addressed?

Common false positives and their solutions:

• Cross-reactivity with other zinc finger proteins:

  • Validate with multiple antibodies targeting different WT1 epitopes

  • Include absorption controls with immunizing peptide

  • Confirm with genetic knockdown/knockout models

  • Note: Cytoplasmic staining in adenocarcinomas may represent cross-reactivity with unrelated epitopes

• Non-specific binding in high-expressing tissues:

  • Optimize antibody concentration through titration experiments

  • Increase blocking stringency (5% BSA or 10% normal serum)

  • Include competing proteins in blocking solution

  • Use monoclonal antibodies for higher specificity

Common false negatives and their solutions:

• Epitope masking due to protein interactions:

  • Test multiple antibodies targeting different epitopes

  • Optimize antigen retrieval methods (heat-induced vs. enzymatic)

  • Consider extended retrieval times for formalin-fixed tissues

• Isoform specificity limitations:

  • Ensure antibody recognizes relevant isoforms in your model

  • For truncated variants, use N-terminal targeted antibodies

  • Example: Some antibodies detect all isoforms while others miss variants lacking exon 2

• Expression level below detection threshold:

  • Implement signal amplification methods

  • Increase antibody incubation time (overnight at 4°C)

  • Use more sensitive detection systems (e.g., SuperSignal™ for WB)

Application-specific troubleshooting:

How do fixation and sample preparation methods affect WT1 antibody performance in different applications?

Fixation and sample preparation significantly impact WT1 antibody performance across applications:

Effect of fixation on epitope accessibility:

• Formalin fixation (FFPE samples):

  • Causes cross-linking of proteins that may mask epitopes

  • Requires optimization of antigen retrieval methods:

    • Heat-induced epitope retrieval (HIER): Citrate buffer pH 6.0 or EDTA buffer pH 9.0

    • Pressure cooker methods often superior to microwave

  • Fixation time critical: over-fixation reduces antibody binding

  • Recommended: 10% neutral buffered formalin for 12-24 hours

• Fresh-frozen samples:

  • Preserve native epitopes but may have poorer morphology

  • Brief fixation (10 min) with cold acetone or methanol recommended

  • Superior for detecting certain WT1 epitopes sensitive to cross-linking

• Cell preparations for flow cytometry:

  • Gentle fixation with 1-2% paraformaldehyde

  • Permeabilization critical for nuclear WT1 detection

  • Commercial permeabilization solutions optimal for consistent results

Sample preparation considerations:

• Tissue processing variables:

  • Section thickness: 4-5μm optimal for IHC

  • Storage of cut sections affects antigenicity (use within 1 week)

  • Paraffin removal must be complete to avoid interference

• Cell lysis for Western blot/IP:

  • Nuclear extraction protocols critical for complete WT1 recovery

  • Addition of DNase improves release from chromatin

  • Protease inhibitors essential to prevent degradation

  • RIPA buffer effective for most applications

• Recommendations for challenging samples:

  • Decalcification of bone samples requires extended antigen retrieval

  • Highly fibrotic tissues benefit from prolonged protein digestion steps

  • Necrotic samples may show non-specific binding requiring additional blocking

Optimization strategy:

• Test multiple fixation/preparation methods with the same antibody

• Include positive control tissues with known WT1 expression patterns

• Document optimal conditions for each application and tissue type

What quantitative methods provide the most accurate assessment of WT1 expression using antibody-based techniques?

Accurate quantitative assessment of WT1 expression requires standardized methodologies:

Western blot quantification:

• Density-based quantification:

  • Include recombinant WT1 protein standards at known concentrations

  • Use reference protein (β-actin, GAPDH) for normalization

  • Employ digital image analysis software with linear dynamic range

  • Report as relative density units normalized to loading controls

• Multiplex fluorescent Western blot:

  • Simultaneous detection of WT1 and reference proteins

  • Eliminates stripping/reprobing variability

  • Provides broader linear detection range

  • More accurate for samples with extreme expression differences

Flow cytometry quantification:

• Mean/median fluorescence intensity (MFI):

  • Use quantitative fluorescent beads for standardization

  • Report as molecules of equivalent soluble fluorochrome (MESF)

  • Include isotype controls for background subtraction

  • Standardize with WT1-expressing cell lines as biological controls

• Multiparameter analysis:

  • Gate on specific cell populations before quantifying WT1

  • Reduces variability from heterogeneous samples

  • Particularly valuable for blood/bone marrow samples

Immunohistochemistry quantification:

• Digital pathology approaches:

  • Whole slide scanning with automated analysis

  • H-score calculation: (% cells 1+ × 1) + (% cells 2+ × 2) + (% cells 3+ × 3)

  • Standardize staining with reference samples in each batch

  • Report both intensity and percentage of positive cells

• Tissue microarray standardization:

  • Include reference tissues in each TMA

  • Use automated staining platforms for consistency

  • Implement internal quality control metrics

ELISA-based quantification for secreted/circulating WT1:

• Standard curve approach:

  • Generate standard curves with recombinant WT1 protein

  • Assess linearity across expected concentration range

  • Include spike-recovery experiments to validate accuracy

• Multiplex bead arrays:

  • Simultaneous quantification of WT1 with other biomarkers

  • Reduced sample volume requirements

  • Expanded dynamic range compared to traditional ELISA

For maximum reliability, consider combining multiple quantitative approaches and include appropriate biological controls representing high, medium, and low WT1 expression.

How are WT1 antibodies being used in vaccine development research and what methodological advances are improving this work?

WT1 antibodies are integral to multiple aspects of vaccine development research:

Key methodological applications in vaccine development:

• Vaccine construct validation:

  • Verification of truncated WT1 expression in vaccine vectors

  • Assessment of intracellular localization in antigen-presenting cells

  • Example: Ad-tWT1 (truncated WT1 lacking zinc finger domains) showed cytoplasmic rather than nuclear expression in dendritic cells despite encoding a transcription factor

• Multi-epitope vaccine design:

  • Epitope mapping using antibody competition assays

  • Confirmation of epitope exposure in vaccine constructs

  • Recent research: Development of multi-epitope vaccines using immuno-informatics approaches targeting WT1 for glioblastoma treatment

• Immune response monitoring:

  • Detection of vaccine-induced anti-WT1 antibodies

  • Characterization of antibody classes and subclasses

  • Correlation with clinical outcomes and survival

Methodological advances:

• Novel antibody formats for improved detection:

  • Single-chain variable fragments (scFvs) for improved tissue penetration

  • Bispecific antibodies targeting WT1 and immune cell markers

  • Nanobodies with superior binding properties

• Advanced immune monitoring platforms:

  • Multiplexed detection of antibodies against multiple WT1 epitopes

  • Single B-cell antibody sequencing to characterize vaccine-induced responses

  • Spatial analysis of immune responses in tumor microenvironment

• In silico approaches complementing antibody studies:

  • Computational prediction of B and T cell epitopes

  • Molecular docking to study receptor interactions

  • Simulation of immune responses to vaccine candidates

The most recent advancements include in-silico vaccine modeling to predict B and T cell binding epitopes, antigenicity, and immune responses against glioblastoma. These computational approaches are laying foundations for experimental studies to develop novel GBM immunotherapies targeting WT1 .

What role do WT1 antibodies play in understanding the dual function of WT1 as both tumor suppressor and oncogene?

WT1 antibodies are crucial tools for elucidating the complex dual role of WT1:

Investigating context-dependent WT1 functions:

• Isoform-specific functions:

  • Differential antibody staining of splice variants (+/- KTS, +/- exon 5)

  • Correlation of isoform expression with tumor phenotypes

  • Distinct subcellular localization patterns of different isoforms

  • Finding: Different isoforms may preferentially function as tumor suppressors or oncogenes

• Protein-protein interaction studies:

  • Co-immunoprecipitation with WT1 antibodies to identify binding partners

  • Proximity ligation assays to confirm interactions in situ

  • ChIP-seq to identify differential DNA binding in different contexts

  • Evidence: WT1 can repress different functional classes of transcriptional activation domains

• Post-translational modification analysis:

  • Phospho-specific WT1 antibodies to detect activation states

  • Ubiquitination studies to assess protein turnover

  • SUMOylation effects on transcriptional activity

Methodological approaches:

• Cell-type specific expression profiling:

  • Multiplex immunofluorescence with lineage markers

  • Single-cell analysis of WT1 expression in heterogeneous samples

  • Laser capture microdissection combined with immunostaining

• Functional domain analysis:

  • Antibodies targeting specific functional domains (N-terminal regulatory domain vs. zinc fingers)

  • Structure-function studies with truncated variants

  • Finding: N-terminal 180 amino acids contain domains responsible for repressing activators that stimulate initiation and/or elongation

• Transcriptional regulation studies:

  • ChIP-seq with WT1 antibodies in different cellular contexts

  • Integration with transcriptomic data to identify context-dependent targets

  • Nuclear run-on assays showing WT1 inhibits transcription initiation

Research has demonstrated that WT1 can repress all three classes of activation domains: those that stimulate initiation (Sp1, CTF), those that stimulate elongation (HIV-1 Tat), and those that stimulate both (VP16, p53, E2F1) . This multifaceted repression capability helps explain its complex role in different cellular contexts.

What cutting-edge techniques are enhancing the use of WT1 antibodies in single-cell and spatial transcriptomics research?

Integration of WT1 antibodies with emerging single-cell and spatial technologies is advancing cancer research:

Single-cell applications:

• CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing):

  • Conjugation of WT1 antibodies to oligonucleotide barcodes

  • Simultaneous measurement of WT1 protein and transcriptome in single cells

  • Reveals discordance between mRNA and protein expression

  • Application: Identifying rare WT1-expressing stem-like cells in heterogeneous tumors

• Single-cell CyTOF (mass cytometry):

  • Metal-tagged WT1 antibodies for high-parameter analysis

  • Detection of WT1 alongside 40+ other proteins

  • Clustering algorithms identify novel cell populations based on WT1 expression patterns

  • Advantage: No spectral overlap issues compared to fluorescence

• scATAC-seq with antibody integration:

  • Combining chromatin accessibility with WT1 protein detection

  • Links epigenetic state to WT1 expression at single-cell level

  • Provides insights into regulatory mechanisms of WT1 expression

Spatial transcriptomics innovations:

• Multiplexed immunofluorescence with signal amplification:

  • Cyclic immunofluorescence allows 20+ antibodies on same section

  • WT1 detection alongside tumor microenvironment markers

  • Tyramide signal amplification enhances sensitivity for low abundance targets

  • Application: Mapping WT1 expression relative to immune infiltrates

• In situ sequencing with protein detection:

  • RNA detection with parallel WT1 antibody staining

  • Spatial correlation between WT1 mRNA and protein

  • Investigation of post-transcriptional regulation mechanisms

• Imaging mass cytometry:

  • Laser ablation of tissue with metal-tagged WT1 antibodies

  • Subcellular resolution of WT1 localization

  • Simultaneous detection of WT1 with tissue architecture markers

  • Application: Tumor heterogeneity mapping with precise spatial context

Computational integration approaches:

• Multi-omics data integration:

  • Algorithms connecting WT1 protein expression with transcriptomic/genomic data

  • Pseudotime trajectory analysis correlating WT1 with differentiation states

  • Network analysis identifying WT1-associated regulatory circuits

• AI-enhanced image analysis:

  • Deep learning algorithms for automated WT1+ cell identification

  • Pattern recognition of subcellular localization changes

  • Classification of tumor regions based on WT1 expression patterns

These advanced technologies are particularly valuable for studying WT1 in cancers with complex heterogeneity such as glioblastoma, where understanding the spatial relationship between WT1-expressing cells and the tumor microenvironment may reveal new therapeutic opportunities.

How do different WT1 antibody types compare in specificity and sensitivity across various research applications?

Different WT1 antibody types exhibit varying performance characteristics across applications:

Comparative performance of antibody types:

Application-specific sensitivity comparison:

• Western blot detection limits:

  • Monoclonal: ~0.1-0.5 ng of recombinant protein

  • Polyclonal: ~0.05-0.2 ng of recombinant protein

  • Enhanced chemiluminescence improves sensitivity ~5-10 fold for both

• IHC sensitivity thresholds:

  • Signal amplification required for detection in samples with physiological expression

  • Polyclonal antibodies typically detect lower expression levels

  • Monoclonal antibodies provide cleaner background for diagnostic applications

• Flow cytometry sensitivity:

  • Intracellular detection requires optimal permeabilization

  • Signal-to-noise ratio generally better with monoclonal antibodies

  • Recommended concentration: 0.40 μg per 10^6 cells in 100 μl suspension

Epitope-specific considerations:

• N-terminal targeting antibodies:

  • Detect truncated variants lacking zinc fingers

  • Recognize multiple isoforms including those lacking exon 2

  • Essential for detecting engineered truncated proteins in vaccine studies

• Zinc finger domain antibodies:

  • May have epitope masking in active transcription complexes

  • Critical for studying DNA-binding functions

  • May miss truncated disease-relevant variants

• Phospho-specific antibodies:

  • Enable studies of WT1 activation state

  • Typically lower sensitivity requiring enrichment steps

  • Valuable for signaling pathway analysis

For critical research applications, validation with multiple antibody types targeting different epitopes is strongly recommended to confirm specificity and rule out isoform-specific effects.

What are the best approaches for multiplexing WT1 antibodies with other cancer biomarkers for comprehensive tumor profiling?

Effective multiplexing of WT1 with other biomarkers requires strategic planning:

Multiplex immunofluorescence optimization:

• Panel design considerations:

  • Antibody species selection to avoid cross-reactivity

  • Fluorophore selection to minimize spectral overlap

  • Combined nuclear and membrane marker detection

  • Example panel for mesothelioma: WT1 (nuclear) + Calretinin + D2-40 + CK5/6 + TTF1 (negative marker)

• Sequential staining approaches:

  • Tyramide signal amplification (TSA) with antibody stripping

  • Multiple rounds of staining with same fluorophore

  • Preserves tissue integrity while expanding marker number

  • Critical for scarce biopsy samples

• Spectral unmixing techniques:

  • Multispectral imaging systems for overlapping fluorophores

  • Reference spectra for each fluorophore required

  • Automated unmixing algorithms improve accuracy

Multiplex chromogenic IHC:

• Multiple chromogen detection:

  • WT1 (DAB/brown) with contrasting chromogens (e.g., Red, Blue)

  • Optimized for routine clinical pathology workflows

  • Less quantitative than fluorescence but more stable

  • Simultaneous analysis of tumor cells and microenvironment

• Digital pathology integration:

  • Whole slide scanning with color deconvolution algorithms

  • Automated quantification of multiple markers

  • Spatial relationship analysis between markers

Mass cytometry applications:

• Suspension-based mass cytometry:

  • Metal-tagged antibodies for non-overlapping detection

  • 30+ markers including WT1 and other cancer biomarkers

  • Single-cell resolution with high-dimensional analysis

  • Ideal for blood cancers and dissociated solid tumors

• Imaging mass cytometry:

  • Preserves spatial context in tissue sections

  • Resolution approaching single-cell level

  • Metal-tagged antibodies enable 40+ marker detection

  • Particularly valuable for tumor microenvironment studies

Computational analysis approaches:

• Supervised classification algorithms:

  • Training data for specific tumor types based on marker patterns

  • Machine learning for automated diagnosis

  • Inclusion of WT1 improves accuracy for mesothelioma and other tumors

• Hierarchical clustering analysis:

  • Identification of tumor subtypes based on marker co-expression

  • Correlation of WT1 with prognosis and treatment response

  • Patient stratification for targeted therapy approaches